Intrinsic value of REGENXBIO - RGNX

Previous Close

$33.20

  Intrinsic Value

$1.35

stock screener

  Rating & Target

str. sell

-96%

  Value-price divergence*

-149%

Previous close

$33.20

 
Intrinsic value

$1.35

 
Up/down potential

-96%

 
Rating

str. sell

 
Value-price divergence*

-149%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of RGNX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.0

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  -37.50
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  5
  8
  12
  18
  27
  38
  52
  70
  92
  118
  149
  185
  226
  273
  324
  381
  444
  511
  584
  661
  743
  830
  921
  1,017
  1,118
  1,223
  1,332
  1,446
  1,565
  1,688
  1,816
Variable operating expenses, $m
 
  30
  47
  70
  102
  144
  198
  265
  348
  448
  566
  703
  860
  1,036
  1,233
  1,450
  1,686
  1,942
  2,218
  2,512
  2,824
  3,154
  3,501
  3,866
  4,248
  4,647
  5,063
  5,496
  5,946
  6,415
  6,901
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  70
  30
  47
  70
  102
  144
  198
  265
  348
  448
  566
  703
  860
  1,036
  1,233
  1,450
  1,686
  1,942
  2,218
  2,512
  2,824
  3,154
  3,501
  3,866
  4,248
  4,647
  5,063
  5,496
  5,946
  6,415
  6,901
Operating income, $m
  -65
  -22
  -35
  -52
  -75
  -106
  -146
  -196
  -257
  -330
  -417
  -518
  -633
  -764
  -908
  -1,068
  -1,243
  -1,431
  -1,634
  -1,851
  -2,081
  -2,324
  -2,580
  -2,849
  -3,130
  -3,424
  -3,730
  -4,049
  -4,381
  -4,727
  -5,085
EBITDA, $m
  -64
  -22
  -33
  -50
  -72
  -102
  -140
  -189
  -248
  -319
  -402
  -500
  -611
  -736
  -876
  -1,030
  -1,198
  -1,380
  -1,576
  -1,785
  -2,006
  -2,241
  -2,488
  -2,747
  -3,018
  -3,302
  -3,597
  -3,905
  -4,225
  -4,558
  -4,904
Interest expense (income), $m
  0
  0
  0
  1
  1
  2
  3
  4
  5
  7
  9
  11
  14
  17
  21
  25
  29
  34
  39
  45
  51
  57
  64
  71
  79
  86
  94
  103
  112
  121
  131
Earnings before tax, $m
  -63
  -22
  -35
  -52
  -76
  -108
  -148
  -199
  -262
  -337
  -426
  -529
  -647
  -781
  -929
  -1,093
  -1,272
  -1,465
  -1,673
  -1,896
  -2,132
  -2,381
  -2,644
  -2,920
  -3,209
  -3,510
  -3,825
  -4,152
  -4,493
  -4,848
  -5,216
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -63
  -22
  -35
  -52
  -76
  -108
  -148
  -199
  -262
  -337
  -426
  -529
  -647
  -781
  -929
  -1,093
  -1,272
  -1,465
  -1,673
  -1,896
  -2,132
  -2,381
  -2,644
  -2,920
  -3,209
  -3,510
  -3,825
  -4,152
  -4,493
  -4,848
  -5,216

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  90
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  173
  133
  206
  308
  447
  631
  867
  1,164
  1,528
  1,966
  2,484
  3,084
  3,771
  4,545
  5,407
  6,358
  7,396
  8,520
  9,727
  11,016
  12,386
  13,833
  15,357
  16,957
  18,631
  20,380
  22,204
  24,103
  26,079
  28,134
  30,270
Adjusted assets (=assets-cash), $m
  83
  133
  206
  308
  447
  631
  867
  1,164
  1,528
  1,966
  2,484
  3,084
  3,771
  4,545
  5,407
  6,358
  7,396
  8,520
  9,727
  11,016
  12,386
  13,833
  15,357
  16,957
  18,631
  20,380
  22,204
  24,103
  26,079
  28,134
  30,270
Revenue / Adjusted assets
  0.060
  0.060
  0.058
  0.058
  0.060
  0.060
  0.060
  0.060
  0.060
  0.060
  0.060
  0.060
  0.060
  0.060
  0.060
  0.060
  0.060
  0.060
  0.060
  0.060
  0.060
  0.060
  0.060
  0.060
  0.060
  0.060
  0.060
  0.060
  0.060
  0.060
  0.060
Average production assets, $m
  3
  4
  6
  9
  13
  19
  26
  35
  46
  59
  75
  93
  113
  136
  162
  191
  222
  256
  292
  330
  372
  415
  461
  509
  559
  611
  666
  723
  782
  844
  908
Working capital, $m
  83
  -11
  -17
  -26
  -38
  -53
  -73
  -98
  -128
  -165
  -209
  -259
  -317
  -382
  -454
  -534
  -621
  -716
  -817
  -925
  -1,040
  -1,162
  -1,290
  -1,424
  -1,565
  -1,712
  -1,865
  -2,025
  -2,191
  -2,363
  -2,543
Total debt, $m
  0
  7
  16
  30
  48
  73
  104
  144
  192
  251
  319
  399
  490
  593
  708
  835
  973
  1,122
  1,283
  1,454
  1,636
  1,829
  2,032
  2,244
  2,467
  2,700
  2,942
  3,195
  3,458
  3,731
  4,015
Total liabilities, $m
  11
  18
  27
  41
  59
  84
  115
  155
  203
  262
  330
  410
  501
  604
  719
  846
  984
  1,133
  1,294
  1,465
  1,647
  1,840
  2,043
  2,255
  2,478
  2,711
  2,953
  3,206
  3,469
  3,742
  4,026
Total equity, $m
  162
  116
  179
  267
  388
  547
  752
  1,009
  1,325
  1,705
  2,153
  2,674
  3,269
  3,940
  4,688
  5,512
  6,412
  7,386
  8,433
  9,551
  10,738
  11,993
  13,315
  14,702
  16,153
  17,670
  19,251
  20,898
  22,611
  24,392
  26,244
Total liabilities and equity, $m
  173
  134
  206
  308
  447
  631
  867
  1,164
  1,528
  1,967
  2,483
  3,084
  3,770
  4,544
  5,407
  6,358
  7,396
  8,519
  9,727
  11,016
  12,385
  13,833
  15,358
  16,957
  18,631
  20,381
  22,204
  24,104
  26,080
  28,134
  30,270
Debt-to-equity ratio
  0.000
  0.060
  0.090
  0.110
  0.130
  0.130
  0.140
  0.140
  0.150
  0.150
  0.150
  0.150
  0.150
  0.150
  0.150
  0.150
  0.150
  0.150
  0.150
  0.150
  0.150
  0.150
  0.150
  0.150
  0.150
  0.150
  0.150
  0.150
  0.150
  0.150
  0.150
Adjusted equity ratio
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867
  0.867

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -63
  -22
  -35
  -52
  -76
  -108
  -148
  -199
  -262
  -337
  -426
  -529
  -647
  -781
  -929
  -1,093
  -1,272
  -1,465
  -1,673
  -1,896
  -2,132
  -2,381
  -2,644
  -2,920
  -3,209
  -3,510
  -3,825
  -4,152
  -4,493
  -4,848
  -5,216
Depreciation, amort., depletion, $m
  1
  1
  1
  2
  3
  4
  5
  7
  9
  12
  15
  19
  23
  27
  32
  38
  44
  51
  58
  66
  74
  83
  92
  102
  112
  122
  133
  145
  156
  169
  182
Funds from operations, $m
  -44
  -22
  -34
  -50
  -73
  -104
  -143
  -192
  -253
  -325
  -411
  -511
  -625
  -753
  -897
  -1,055
  -1,227
  -1,414
  -1,615
  -1,830
  -2,057
  -2,298
  -2,552
  -2,818
  -3,097
  -3,388
  -3,692
  -4,008
  -4,337
  -4,679
  -5,034
Change in working capital, $m
  5
  -4
  -6
  -9
  -12
  -15
  -20
  -25
  -31
  -37
  -43
  -50
  -58
  -65
  -72
  -80
  -87
  -94
  -101
  -108
  -115
  -122
  -128
  -134
  -141
  -147
  -153
  -160
  -166
  -173
  -179
Cash from operations, $m
  -49
  -17
  -28
  -42
  -62
  -88
  -123
  -167
  -222
  -288
  -368
  -460
  -567
  -688
  -824
  -975
  -1,140
  -1,320
  -1,514
  -1,721
  -1,942
  -2,177
  -2,424
  -2,684
  -2,956
  -3,241
  -3,538
  -3,848
  -4,171
  -4,506
  -4,855
Maintenance CAPEX, $m
  0
  -1
  -1
  -1
  -2
  -3
  -4
  -5
  -7
  -9
  -12
  -15
  -19
  -23
  -27
  -32
  -38
  -44
  -51
  -58
  -66
  -74
  -83
  -92
  -102
  -112
  -122
  -133
  -145
  -156
  -169
New CAPEX, $m
  -8
  -2
  -2
  -3
  -4
  -6
  -7
  -9
  -11
  -13
  -16
  -18
  -21
  -23
  -26
  -29
  -31
  -34
  -36
  -39
  -41
  -43
  -46
  -48
  -50
  -52
  -55
  -57
  -59
  -62
  -64
Cash from investing activities, $m
  19
  -3
  -3
  -4
  -6
  -9
  -11
  -14
  -18
  -22
  -28
  -33
  -40
  -46
  -53
  -61
  -69
  -78
  -87
  -97
  -107
  -117
  -129
  -140
  -152
  -164
  -177
  -190
  -204
  -218
  -233
Free cash flow, $m
  -30
  -19
  -30
  -46
  -68
  -97
  -134
  -181
  -240
  -311
  -395
  -493
  -606
  -734
  -877
  -1,036
  -1,209
  -1,398
  -1,601
  -1,818
  -2,050
  -2,294
  -2,553
  -2,824
  -3,108
  -3,405
  -3,715
  -4,038
  -4,375
  -4,724
  -5,088
Issuance/(repayment) of debt, $m
  0
  7
  10
  14
  18
  24
  31
  39
  48
  58
  69
  80
  91
  103
  115
  126
  138
  149
  161
  171
  182
  193
  203
  213
  223
  233
  243
  253
  263
  273
  284
Issuance/(repurchase) of shares, $m
  0
  66
  98
  141
  197
  267
  353
  456
  578
  717
  875
  1,050
  1,243
  1,452
  1,677
  1,917
  2,172
  2,439
  2,720
  3,014
  3,319
  3,636
  3,965
  4,307
  4,660
  5,027
  5,406
  5,799
  6,206
  6,629
  7,067
Cash from financing (excl. dividends), $m  
  0
  73
  108
  155
  215
  291
  384
  495
  626
  775
  944
  1,130
  1,334
  1,555
  1,792
  2,043
  2,310
  2,588
  2,881
  3,185
  3,501
  3,829
  4,168
  4,520
  4,883
  5,260
  5,649
  6,052
  6,469
  6,902
  7,351
Total cash flow (excl. dividends), $m
  -29
  53
  77
  108
  147
  195
  251
  315
  386
  464
  548
  636
  728
  821
  914
  1,008
  1,100
  1,191
  1,280
  1,367
  1,451
  1,534
  1,616
  1,696
  1,775
  1,854
  1,933
  2,013
  2,095
  2,178
  2,264
Retained Cash Flow (-), $m
  55
  -66
  -98
  -141
  -197
  -267
  -353
  -456
  -578
  -717
  -875
  -1,050
  -1,243
  -1,452
  -1,677
  -1,917
  -2,172
  -2,439
  -2,720
  -3,014
  -3,319
  -3,636
  -3,965
  -4,307
  -4,660
  -5,027
  -5,406
  -5,799
  -6,206
  -6,629
  -7,067
Prev. year cash balance distribution, $m
 
  90
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  77
  -21
  -33
  -49
  -72
  -103
  -142
  -191
  -252
  -326
  -413
  -515
  -631
  -763
  -909
  -1,071
  -1,248
  -1,440
  -1,647
  -1,867
  -2,102
  -2,350
  -2,611
  -2,885
  -3,173
  -3,473
  -3,786
  -4,112
  -4,451
  -4,804
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  74
  -19
  -28
  -41
  -56
  -74
  -96
  -120
  -145
  -171
  -196
  -220
  -240
  -256
  -267
  -272
  -272
  -265
  -254
  -237
  -217
  -195
  -171
  -147
  -123
  -101
  -81
  -64
  -49
  -36
Current shareholders' claim on cash, %
  100
  87.0
  76.5
  67.8
  60.5
  54.4
  49.2
  44.8
  41.0
  37.7
  34.8
  32.2
  29.9
  27.9
  26.1
  24.5
  23.0
  21.7
  20.4
  19.3
  18.3
  17.3
  16.4
  15.6
  14.9
  14.1
  13.5
  12.8
  12.2
  11.7
  11.2

REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.

FINANCIAL RATIOS  of  REGENXBIO (RGNX)

Valuation Ratios
P/E Ratio -14
Price to Sales 175.8
Price to Book 5.4
Price to Tangible Book
Price to Cash Flow -17.9
Price to Free Cash Flow -15.4
Growth Rates
Sales Growth Rate -37.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 700%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0.1
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -32%
Ret/ On Assets - 3 Yr. Avg. -61.7%
Return On Total Capital -33.2%
Ret/ On T. Cap. - 3 Yr. Avg. 26.5%
Return On Equity -33.2%
Return On Equity - 3 Yr. Avg. 15.3%
Asset Turnover 0
Profitability Ratios
Gross Margin 80%
Gross Margin - 3 Yr. Avg. 79.4%
EBITDA Margin -1240%
EBITDA Margin - 3 Yr. Avg. -531.4%
Operating Margin -1300%
Oper. Margin - 3 Yr. Avg. -551.4%
Pre-Tax Margin -1260%
Pre-Tax Margin - 3 Yr. Avg. -538.1%
Net Profit Margin -1260%
Net Profit Margin - 3 Yr. Avg. -533.9%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

RGNX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the RGNX stock intrinsic value calculation we used $5 million for the last fiscal year's total revenue generated by REGENXBIO. The default revenue input number comes from 2016 income statement of REGENXBIO. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our RGNX stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for RGNX is calculated based on our internal credit rating of REGENXBIO, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of REGENXBIO.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of RGNX stock the variable cost ratio is equal to 380%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for RGNX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for REGENXBIO.

Corporate tax rate of 27% is the nominal tax rate for REGENXBIO. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the RGNX stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for RGNX are equal to 50%.

Life of production assets of 2.5 years is the average useful life of capital assets used in REGENXBIO operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for RGNX is equal to -140%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $162 million for REGENXBIO - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 29.969 million for REGENXBIO is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of REGENXBIO at the current share price and the inputted number of shares is $1.0 billion.

RELATED COMPANIES Price Int.Val. Rating
DMTX Dimension Ther 6.00 0.23  str.sell
VYGR Voyager Therap 20.53 1.93  str.sell
SGMO Sangamo Therap 14.85 0.55  str.sell
ONCE Spark Therapeu 85.53 2.34  str.sell
AGTC Applied Geneti 3.80 1.52  str.sell

COMPANY NEWS

▶ Gene Therapies: A Foot in the Door   [Oct-13-17 12:31PM  Barrons.com]
▶ ETFs with exposure to REGENXBIO, Inc. : October 9, 2017   [Oct-09-17 11:59AM  Capital Cube]
▶ After bidding war, North Bay drug maker snags gene therapy company for $151 million   [Oct-03-17 02:35PM  American City Business Journals]
▶ Ultragenyx to Acquire Dimension Therapeutics   [08:30AM  GlobeNewswire]
▶ RegenxBio declines to push forward on planned acquisition   [Oct-02-17 02:25PM  American City Business Journals]
▶ 8 Stocks for the Next Gene Revolution   [Sep-29-17 06:00AM  Investopedia]
▶ Gene Therapy: A Big Week for Many Names   [Sep-25-17 09:57AM  Barrons.com]
▶ Rockville biotech buys Cambridge gene therapy firm for $86M   [Aug-25-17 12:40PM  American City Business Journals]
▶ Cambridge gene therapy firm Dimension Therapeutics to be acquired   [11:25AM  American City Business Journals]
▶ REGENXBIO to Acquire Dimension Therapeutics   [08:00AM  GlobeNewswire]
▶ Regenxbio reports 2Q loss   [12:33AM  Associated Press]
▶ ETFs with exposure to REGENXBIO, Inc. : June 15, 2017   [Jun-15-17 03:08PM  Capital Cube]
▶ ETFs with exposure to REGENXBIO, Inc. : June 5, 2017   [Jun-05-17 02:42PM  Capital Cube]
▶ Regenxbio reports 1Q loss   [May-09-17 06:36PM  Associated Press]
▶ REGENXBIO Enhances and Expands Scientific Leadership   [Mar-28-17 07:00AM  GlobeNewswire]
▶ Regenxbio Leads Biotech Movers Ahead of Market's Open   [Mar-22-17 09:31AM  TheStreet.com]
▶ 6 Stocks Trending Up With Big Volume   [Mar-09-17 04:45PM  TheStreet.com]
▶ REGENXBIO Honors Rare Disease Day┬« 2017   [07:00AM  GlobeNewswire]
▶ D.C.-area biotech stocks fall on Trump's tough talk on industry   [Jan-11-17 11:10PM  at bizjournals.com]
▶ Hedge Funds Are Betting On Regenxbio Inc (RGNX)   [Dec-08-16 07:30AM  at Insider Monkey]
Financial statements of RGNX
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.